Clinical trial
A Phase II Prospective Non-Randomized Clinical Trial of Dose-Adjusted Schedule of Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma Who Did Not Receive Prior Systemic Therapy or Have Been Treated With Single Agent Targretin
NCT00958074 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Prospective Non-Randomized Clinical Trial of Dose-Adjusted Schedule of Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma Who Did Not Receive Prior Systemic Therapy or Have Been Treated With Single Agent Targretin
- Lead sponsor
- University of Washington
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- July 31, 2009
- Completion date
- November 30, 2013
- Enrollment
- 11 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
cutaneous t-cell lymphoma stage i, cutaneous t-cell lymphoma stage ii, cutaneous t-cell lymphoma stage iii, cutaneous t-cell lymphoma stage iv